Clinical Trial Update: Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease. [Phase 4]

View source ↗

Summary

A Phase 4 study evaluating compliance and tolerability of rivastigmine transdermal patch 10 cm² in patients with probable Alzheimer's disease, with study status…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Exelon Patch (rivastigmine transdermal patch) 10 cm² (rivastigmine transdermal patch)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Alzheimer's Disease | Phase 4 | Status: COMPLETED